sales@businessmarketinsights.com   UK: +442030260021  , US: +16467917070  , Toll Free: 1800 121 6455
Pharmaceuticals Asia Pacific Cardiometabolic Diseases Market...

Marktprognose für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum bis 2028 – Auswirkungen von COVID-19 und regionale Analyse nach Typ (Herz-Kreislauf-Erkrankung (CVD), Typ-2-Diabetes, Bluthochdruck und Fettleibigkeit), Behandlung (ACE-Hemmer, Diuretika, Glucophage und andere), Dosierung ( Tablette und Injektion), Verabreichungsweg (oral und intravenös), Endbenutzer (Krankenhaus, Klinik und häusliche Pflege) und Vertriebskanal (Krankenhausapotheke, Einzelhandelsapotheke und Online-Apotheke)

TIPRE00026135 | Pages: 185 | Pharmaceuticals | Nov 2021 | Type: Regional | Status: Published

Markteinführung

Die kardiometabolische Erkrankung ist durch eine Gruppe von Anomalien und Symptomen gekennzeichnet, die auftreten das Risiko, dass Personen eine Herz-Kreislauf-Erkrankung entwickeln. Zu den Symptomen gehören Bluthochdruck, Fettleibigkeit, Insulinresistenz, Dyslipidämie, schlechtes Cholesterinprofil (LDL) und Glukosetoleranz. Personen, die am kardiometabolischen Syndrom leiden, sind anfällig für mehrere andere lebensbedrohliche Krankheiten wie Typ-2-Diabetes, Schlaganfall, koronare Herzkrankheit (KHK), Herz-Kreislauf-Erkrankungen (CVD) und viele andere.

Darüber hinaus wird erwartet, dass die zunehmende Prävalenz kardiometabolischer Erkrankungen das Marktwachstum im Prognosezeitraum ankurbeln wird. Allerdings schränkt die Unterdiagnose von Herz-Kreislauf-Erkrankungen in Ländern mit niedrigem und mittlerem Einkommen (LMICs) das Wachstum des Marktes für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum ein.

Die Unterbrechungen der Lieferkette und die massive Nachfrage nach Effiziente Behandlungen zur Therapie von COVID-19 haben die Gesundheitsforschungsbranche im asiatisch-pazifischen Raum in eine entscheidende Situation gebracht. Es wurden Verbotsmaßnahmen ergriffen, um die Ausbreitung dieser Pandemie einzudämmen. Die COVID-19-Pandemie hat weitreichende Auswirkungen auf die Volkswirtschaften im asiatisch-pazifischen Raum. Länder wie Indien (31.769.132), Japan (956.407), China (93.289) und Südkorea (203.926) waren von der Pandemie negativ betroffen. Die Sozioökonomie wurde stark beeinträchtigt, da die negative Inflation, das BIP und ein regionaler Anstieg der Arbeitslosigkeit zunahmen. In Japan kommt es in letzter Zeit immer häufiger zu Patienten mit Bluthochdruck und Fettleibigkeit. Bei diesen Patienten besteht ein außergewöhnlich hohes Risiko für einen schweren Verlauf bei COVID-19 und sie bedürfen daher einer sorgfältigen Beobachtung und intensiven Behandlung. Ähnlich wie bei Bluthochdruck ist die Definition von Fettleibigkeit in den verschiedenen Studien/Ländern nicht konstant, was berücksichtigt werden muss. Es ist jedoch wichtig zu beachten, dass der therapeutische Mechanismus von CCB gegen COVID-19 noch auf weitere Untersuchungen und randomisierte kontrollierte klinische Studien wartet.

Marktübersicht und Dynamik

Der Markt für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum wird bis 2028 voraussichtlich 28.953,2 Millionen US-Dollar erreichen, gegenüber 21.091,3 Millionen US-Dollar im Jahr 2021; Es wird erwartet, dass sie von 2021 bis 2028 mit einer durchschnittlichen jährlichen Wachstumsrate von 4,6 % wachsen wird. Kardiometabolische Erkrankungen (CMDs) sind eine der häufigsten Todesursachen weltweit. Diese Krankheiten werden hauptsächlich durch einen ungesunden Lebensstil, Bewegungsmangel, Rauchen und ungesunde Ernährung verursacht. CMDs umfassen Herz-Kreislauf-Erkrankungen (CVDs), Diabetes mellitus und chronisches Nierenversagen. Die meisten Herz-Kreislauf-Erkrankungen können verhindert werden, indem verhaltensbedingte Risikofaktoren wie Tabakkonsum, ungesunde Ernährungsgewohnheiten, Fettleibigkeit, körperliche Inaktivität und Alkoholkonsum angegangen werden. Diabetes gehört zu den lebensbedrohlichen chronischen Erkrankungen, für die es keine funktionelle Heilung gibt. Es führt zu verschiedenen Komplikationen und erhöht insgesamt das Risiko eines vorzeitigen Todes. Herzinfarkt, Schlaganfall, Nierenversagen, Beinamputation, Sehverlust und Nervenschäden sind die häufigsten Komplikationen im Zusammenhang mit Diabetes. Aufgrund zunehmenden Rauchens, Bewegungsmangels, Alkoholkonsums und ungesunder Ernährungsgewohnheiten steigt die Zahl der Menschen mit einer oder mehreren CMDs. Die zunehmende Prävalenz von Fettleibigkeit führt dazu, dass auch die Patientenbasis an CMDs leidet. Mit diesem raschen Anstieg der Prävalenz von CMDs ist der Bedarf an geeigneten Behandlungen für Herz-Kreislauf-Erkrankungen sprunghaft angestiegen, was zu einem enormen Wachstum des Marktes für Herz-Kreislauf-Erkrankungen im asiatisch-pazifischen Raum geführt hat.

< u>Wichtige Marktsegmente

In Bezug auf die Art hatte das Segment der Herz-Kreislauf-Erkrankungen im Jahr 2020 den größten Anteil am Markt für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum In Bezug auf die Behandlung hatte das ACE-Hemmer-Segment im Jahr 2020 den größten Anteil am Markt für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum. In Bezug auf die Dosierung hatte das Tablettensegment im Jahr 2020 den größten Anteil am Markt für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum Je nach Verabreichungsweg hatte das orale Segment im Jahr 2020 den größten Anteil am Markt für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum. In Bezug auf den Endverbraucher hatte das Krankenhaussegment im Jahr 2020 den größten Anteil am Markt für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum Was den Vertriebskanal anbelangt, hielt das Segment für Krankenhausapotheken im Jahr 2020 den größten Marktanteil.

Wichtige Quellen und Unternehmen gelistet

Einige wichtige primäre und sekundäre Quellen, auf die bei der Erstellung dieses Berichts über den Markt für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum zurückgegriffen wurde, sind Unternehmenswebsites, Jahresberichte und Finanzberichte , nationale Regierungsdokumente und statistische Datenbanken. Zu den wichtigsten im Bericht aufgeführten Unternehmen gehören Eli Lilly and Company, Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Cardax Inc. und Kowa Company, Ltd.

Bericht über Kaufgründe

  • Um die Marktlandschaft für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum zu verstehen und Marktsegmente zu identifizieren, die wahrscheinlich eine starke Rendite garantieren
  • Um die sich ständig verändernde Marktlandschaft zu verstehen und zu bleiben Vorsprung im Wettbewerb
  • Um Fusionen und Übernahmen sowie Partnerschaftsabkommen im asiatisch-pazifischen Markt für kardiometabolische Erkrankungen effizient zu planen, indem Segmente mit den vielversprechendsten wahrscheinlichen Umsätzen identifiziert werden
  • Um fundierte Geschäftsentscheidungen auf der Grundlage einer scharfsinnigen und umfassenden Analyse der Marktleistung verschiedener Segmente zu treffen
  • Um eine Marktumsatzprognose für den asiatisch-pazifischen Raum zu erhalten Markt für kardiometabolische Erkrankungen basierend auf verschiedenen Segmenten für den Zeitraum 2021–2028 

Marktsegmentierung für kardiometabolische Erkrankungen im asiatisch-pazifischen Raum

Nach Typ

  • Herz-Kreislauf-Erkrankungen (CVD)
  • Typ-2-Diabetes
  • Bluthochdruck
  • Fettleibigkeit 

Durch Behandlung

  • ACE-Hemmer
  • Diuretika
  • Glucophage
  • Andere 

Nach Dosierung

  • Tablette
  • Injektion

Über den Verabreichungsweg

  • Oral
  • Intravenös 

Von Endbenutzern

  • Krankenhaus
  • Klinik
  • Homecare-Einstellungen  ;

Nach Vertriebskanal

  • Krankenhausapotheke
  • Einzelhandelsapotheke
  • Online-Apotheke

Nach Land

  • Asien-Pazifik
  • China
  • Japan
  • Indien
  • Südkorea
  • Australien
  • Übriger Asien-Pazifik

Erwähnte Unternehmen

  • Eli Lilly and Company.    
  • Bayer AG                         
  • Novartis AG               ;     
  • Boehringer Ingelheim International Gmbh
  • Novo Nordisk A/S       
  • AstraZeneca                  
  • Kowa Company, Ltd.
  • Cardax, Inc.

 

1.           Introduction  21

1.1         Scope of the Study. 21

1.2         The Insight Partners Research Report Guidance. 21

1.3         Market Segmentation. 23

1.3.7        Asia Pacific Cardiometabolic Diseases market – By Country. 25

2.           Asia Pacific Cardiometabolic Diseases Market – Key Takeaways  26

3.        Research Methodology  31

3.1         Coverage. 33

3.2         Secondary Research. 33

3.3         Primary Research. 34

4.           Asia Pacific Cardiometabolic Diseases Market – Market Landscape  35

4.1         Overview.. 35

4.2         PEST Analysis. 36

4.3         Expert Opinions. 37

5.           Asia Pacific Cardiometabolic Diseases Market – Key Market Dynamics  38

5.1         Market Drivers. 38

5.1.1        Increasing Prevalence of Cardiometabolic Diseases. 38

5.1.2        Innovation in Cardiometabolic Diseases Therapeutics. 38

5.2         Market Restraints. 39

5.2.1        Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs) 39

5.3         Market Opportunities. 40

5.3.1        Technological Advancements in CMD Diagnosis. 40

5.4         Future Trends. 40

5.4.1        Personalized Treatment for CMDs. 40

5.5         Impact Analysis. 41

6.           Asia Pacific Cardiometabolic Diseases Market – Regional Analysis  42

6.1         Asia Pacific Cardiometabolic Diseases Market Revenue Forecast And Analysis. 42

7.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Type  44

7.1         Overview.. 44

7.2         Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44

7.3         Cardiovascular Disease (CVD) 45

7.3.1        Overview.. 45

7.3.2        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 46

7.4         Hypertension. 47

7.4.1        Overview.. 47

7.4.2        Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 47

7.5         Type 2 Diabetes. 48

7.5.1        Overview.. 48

7.5.2        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 48

7.6         Obesity. 50

7.6.1        Overview.. 50

7.6.2        Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 50

8.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Treatment  52

8.1         Overview.. 52

8.2         Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52

8.3         ACE inhibitors. 53

8.3.1        Overview.. 53

8.3.2        ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn) 53

8.4         Diuretics. 55

8.4.1        Overview.. 55

8.4.2        Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 55

8.5         Glucophage. 56

8.5.1        Overview.. 56

8.5.2        Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 56

8.6         Others. 57

8.6.1        Overview.. 57

8.6.2        Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 57

9.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Dosage  58

9.1         Overview.. 58

9.2         Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58

9.3         Tablet 59

9.3.1        Overview.. 59

9.3.2        Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 59

9.4         Injection. 60

9.4.1        Overview.. 60

9.4.2        Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 60

10.        Asia Pacific Cardiometabolic Diseases Market Analysis – By Route of Administration  61

10.1      Overview.. 61

10.2      Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61

10.3      Oral 62

10.3.1     Overview.. 62

10.3.2     Oral Market Revenue and Forecast to 2028 (US$ Mn) 62

10.4      Intravenous. 64

10.4.1     Overview.. 64

10.4.2     Intravenous Market Revenue and Forecast to 2028 (US$ Mn) 64

11.        Asia Pacific Cardiometabolic Diseases Market Analysis – By End User  66

11.1      Overview.. 66

11.2      Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66

11.3      Clinic. 67

11.3.1     Overview.. 67

11.3.2     Clinic Market Revenue and Forecast to 2028 (US$ Mn) 67

11.4      Hospital 68

11.4.1     Overview.. 68

11.4.2     Hospital Market Revenue and Forecast to 2028 (US$ Mn) 68

11.5      Homecare Settings. 70

11.5.1     Overview.. 70

11.5.2     Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn) 70

12.        Asia Pacific Cardiometabolic Diseases Market Analysis – By Distribution Channel 72

12.1      Overview.. 72

12.2      Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72

12.3      Hospital Pharmacy. 73

12.3.1     Overview.. 73

12.3.2     Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 73

12.4      Retail Pharmacy. 74

12.4.1     Overview.. 74

12.4.2     Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 74

12.5      Online Pharmacy. 76

12.5.1     Overview.. 76

12.5.2     Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 76

13.        Asia Pacific Cardiometabolic Diseases Market – Geographic Analysis  78

13.1      Asia Pacific: Cardiometabolic Diseases Market 78

13.1.1     Overview.. 78

13.1.2     Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 80

13.1.3     Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81

13.1.4     Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028  (USD Million) 81

13.1.5     Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82

13.1.6     Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82

13.1.7     Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83

13.1.8     Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83

13.1.9     Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84

13.1.9.1       China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 85

13.1.9.1.1       China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86

13.1.10  China: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86

13.1.11  China: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87

13.1.12  China: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87

13.1.13  China: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88

13.1.14  China: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88

13.1.15  China: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89

13.1.15.1    Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90

13.1.15.1.1    Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90

13.1.16  Japan: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91

13.1.17  Japan: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92

13.1.18  Japan: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92

13.1.19  Japan: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93

13.1.20  Japan: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93

13.1.21  Japan: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94

13.1.21.1    India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million) 95

13.1.21.1.1    India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96

13.1.22  India: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97

13.1.23  India: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97

13.1.24  India: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98

13.1.25  India: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98

13.1.26  India: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99

13.1.27  India: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99

13.1.27.1    South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100

13.1.27.1.1    South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100

13.1.28  South Korea: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101

13.1.29  South Korea: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102

13.1.30  South Korea: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102

13.1.31  South Korea: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103

13.1.32  South Korea: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103

13.1.33  South Korea: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104

13.1.33.1    Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105

13.1.33.1.1    Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105

13.1.34  Australia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106

13.1.35  Australia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107

13.1.36  Australia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107

13.1.37  Australia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108

13.1.38  Australia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108

13.1.39  Australia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109

13.1.39.1    Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110

13.1.39.1.1    Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110

13.1.40  Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111

13.1.41  Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112

13.1.42  Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112

13.1.43  Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113

13.1.44  Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113

13.1.45  Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114

14.        Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market  115

14.1      Asia Pacific: Impact Assessment of COVID-19 Pandemic. 115

15.        Asia Pacific Cardiometabolic Diseases Market – Industry Landscape  117

15.1      Overview.. 117

15.2      Growth Strategies in the Cardiometabolic Diseases Market (%) 118

15.3      Organic Developments. 119

15.3.1     Overview.. 119

15.4      Inorganic Developments. 122

15.4.1     Overview.. 122

16.        Company Profiles  124

16.1      Eli Lilly and Company. 124

16.1.1     Key Facts. 124

16.1.2     Business Description. 124

16.1.3     Products and Services. 125

16.1.4     Financial Overview.. 127

16.1.5     SWOT Analysis. 130

16.1.6     Key Developments. 131

16.2      Bayer AG.. 134

16.2.1     Key Facts. 134

16.2.2     Business Description. 134

16.2.3     Products and Services. 135

16.2.4     Financial Overview.. 135

16.2.5     SWOT Analysis. 138

16.2.6     Key Developments. 139

16.3      Novartis AG.. 141

16.3.1     Key Facts. 141

16.3.2     Business Description. 141

16.3.3     Products and Services. 142

16.3.4     Financial Overview.. 143

16.3.5     SWOT Analysis. 146

16.3.6     Key Developments. 147

16.4      Boehringer Ingelheim International GmbH.. 148

16.4.1     Key Facts. 148

16.4.2     Business Description. 148

16.4.3     Products and Services. 149

16.4.4     Financial Overview.. 150

16.4.5     SWOT Analysis. 154

16.4.6     Key Developments. 155

16.5      Novo Nordisk A/S. 157

16.5.1     Key Facts. 157

16.5.2     Business Description. 157

16.5.3     Products and Services. 158

16.5.4     Financial Overview.. 159

16.5.5     SWOT Analysis. 162

16.5.6     Key Developments. 163

16.6      AstraZeneca. 165

16.6.1     Key Facts. 165

16.6.2     Business Description. 165

16.6.3     Products and Services. 166

16.6.4     Financial Overview.. 167

16.6.5     SWOT Analysis. 170

16.6.6     Key Developments. 171

16.7      Cardax, Inc. 173

16.7.1     Key Facts. 173

16.7.2     Business Description. 173

16.7.3     Products and Services. 174

16.7.4     Financial Overview.. 174

16.7.5     SWOT Analysis. 177

16.7.6     Key Developments. 177

16.8      Kowa Company, Ltd. 178

16.8.1     Key Facts. 178

16.8.2     Business Description. 178

16.8.3     Products and Services. 179

16.8.4     Financial Overview.. 179

16.8.5     SWOT Analysis. 180

16.8.6     Key Developments. 181

17.        Appendix  182

17.1      About The Insight Partners. 182

17.2      Glossary of Terms. 183

LIST OF TABLES

Table 1.             Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81

Table 2.             Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81

Table 3.             Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82

Table 4.             Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82

Table 5.             Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83

Table 6.             Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83

Table 7.             China Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86

Table 8.             China Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87

Table 9.             China Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87

Table 10.          China Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88

Table 11.          China Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88

Table 12.          China Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89

Table 13.          Japan Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91

Table 14.          Japan Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92

Table 15.          Japan Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92

Table 16.          Japan Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93

Table 17.          Japan Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93

Table 18.          Japan Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94

Table 19.          India Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97

Table 20.          India Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97

Table 21.          India Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98

Table 22.          India Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98

Table 23.          India Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99

Table 24.          India Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99

Table 25.          South Korea Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101

Table 26.          South Korea Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102

Table 27.          South Korea Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102

Table 28.          South Korea Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103

Table 29.          South Korea Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103

Table 30.          South Korea Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104

Table 31.          Australia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106

Table 32.          Australia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107

Table 33.          Australia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107

Table 34.          Australia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108

Table 35.          Australia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108

Table 36.          Australia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109

Table 37.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111

Table 38.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112

Table 39.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112

Table 40.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113

Table 41.          Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113

Table 42.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114

Table 43.          Organic Developments in the Cardiometabolic Diseases Market 119

Table 44.          Inorganic Developments in the Cardiometabolic Diseases Market 123

Table 45.          Glossary of Terms, Asia Pacific Cardiometabolic Diseases Market 183

 

 

LIST OF FIGURES

Figure 1.           Asia Pacific Cardiometabolic Diseases Market Segmentation. 23

Figure 2.           Asia Pacific Cardiometabolic Diseases Market Overview.. 26

Figure 3.           Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Asia Pacific Cardiometabolic Diseases Market 27

Figure 4.           Asia Pacific Cardiometabolic Diseases Market – Leading Country Markets (US$ Million) 28

Figure 5.           Asia Pacific Cardiometabolic Diseases Market, Industry Landscape. 29

Figure 6.           Asia Pacific PEST Analysis. 36

Figure 7.           Asia Pacific Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints. 41

Figure 8.           Asia Pacific Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028. 43

Figure 9.           Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44

Figure 10.        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 46

Figure 11.        Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 47

Figure 12.        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 49

Figure 13.        Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 51

Figure 14.        Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52

Figure 15.        ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 54

Figure 16.        Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 55

Figure 17.        Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 56

Figure 18.        Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 57

Figure 19.        Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58

Figure 20.        Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 59

Figure 21.        Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 60

Figure 22.        Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61

Figure 23.        Oral Market Revenue and Forecasts to 2028 (US$ Mn) 63

Figure 24.        Intravenous Market Revenue and Forecasts to 2028 (US$ Mn) 65

Figure 25.        Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66

Figure 26.        Clinic Market Revenue and Forecasts to 2028 (US$ Mn) 67

Figure 27.        Hospital Market Revenue and Forecasts to 2028 (US$ Mn) 69

Figure 28.        Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn) 71

Figure 29.        Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72

Figure 30.        Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 73

Figure 31.        Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 75

Figure 32.        Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 77

Figure 33.        Asia Pacific: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million) 79

Figure 34.        Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million) 80

Figure 35.        Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84

Figure 36.        China Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86

Figure 37.        Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 91

Figure 38.        India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96

Figure 39.        South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 101

Figure 40.        Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 106

Figure 41.        Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 111

Figure 42.        Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 116

Figure 43.        Growth Strategies in the Cardiometabolic Diseases Market (%) 118

 

 

  1. Eli Lilly and Company.   
  2. Bayer AG             
  3. Novartis AG         
  4. Boehringer Ingelheim International Gmbh
  5. Novo Nordisk A/S            
  6. AstraZeneca         
  7. Kowa Company, Ltd.
  8. Cardax, Inc.       
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cardiometabolic diseases market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports
Report Name Published Date
Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an.. May 2022
Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec.. May 2022
Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an.. May 2022
Purchase Options
Single User License
$3000
$1800
Site License
$4000
$2400
Enterprise License
$5000
$3000
GET FREE SAMPLE PDF
Inquire before Buying Inquire for Discount
Subscription Member Price: FREE
Get Subscription